All In Biotech

Drug Trial Radar · NCT07216560

First-in-human Study of 7MW4911 in GI Cancer

A Phase I/II Study of 7MW4911 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With Advanced Colorectal Cancer and Other Advanced Gastrointestinal Tumors

Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

200

Planned (sponsor's estimate)

Start

Jan 13, 2026

Primary completion

Jul 2027

Study completion Dec 2028

Sponsor

Sponsor type
Industry
First posted
Oct 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is the first-in-human study of 7MW4911 in US patients, to investigate its prelimary safety and efficacy in patients with gastrointestinal cancers.

Conditions

  • GI Cancers

Interventions

  • 7MW4911Drug

    study drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and rates of adverse eventsTime frame: Up to approximately 2 years
  2. MTD, RED, and RP2DTime frame: Up to approximately 2 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Hematology Oncology Associates of the Treasure Coast

    Port Saint Lucie, Florida · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • START

    Long Island City, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • START Moutain Region

    West Valley City, Utah · Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.